María Velasco-de Andrés

Dr. María Velasco-de Andrés

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LALucía Aragón-Serrano
Lucía Aragón-Serrano
LCLaura Carrillo-Serradell
Laura Carrillo-Serradell
VRVioleta Planells Romeo
Violeta Planells Romeo
MIMarcos Isamat
Marcos Isamat
MAMaría Velasco-de Andrés
María Velasco-de Andrés
LFLozano Francisco
Lozano Francisco
Cancer management still requires more potent and safer treatments, of which immunomodulatory receptors on the lymphocyte surface have started to show promise in new cancer immunotherapies (e.g., CTLA-4 and PD-1). CD6 is a signal-transducing transmembrane receptor, mainly expressed by all T cells and some B and NK cell subsets, whose endogenous ligands (CD166/ALCAM, CD318/CDCP-1, Galectins 1 and 3) are overexpressed by malignant cells of different lineages. This places CD6 as a potential target for novel therapies against haematological and non-haematological malignancies. Recent experimental evidence for the role of CD6 in cancer immunotherapies is summarised in this review, dealing with diverse and innovative strategies from the classical use of monoclonal antibodies to soluble recombinant decoys or the adoptive transfer of immune cells engineered with chimeric antigen receptors.

Verified
Journal Article
Open access
PDF file
LCLaura Carrillo-Serradell
Laura Carrillo-Serradell
JLJade Liu-Tindall
Jade Liu-Tindall
VRVioleta Planells Romeo
Violeta Planells Romeo
LALucía Aragón-Serrano
Lucía Aragón-Serrano
MIMarcos Isamat
Marcos Isamat
MAMaría Velasco-de Andrés
María Velasco-de Andrés
The fungal component of microbiota, known as the mycobiome, inhabits different body niches such as the skin and the gastrointestinal, respiratory, and genitourinary tracts. Much information has been gained on the bacterial component of the human microbiota, but the mycobiome has remained somewhat elusive due to its sparsity, variability, susceptibility to environmental factors (e.g., early life colonization, diet, or pharmacological treatments), and the specific in vitro culture challenges. Functionally, the mycobiome is known to play a role in modulating innate and adaptive immune responses by interacting with microorganisms and immune cells. The latter elicits anti-fungal responses via the recognition of specific fungal cell-wall components (e.g., β-1,3-glucan, mannan, and chitin) by immune system receptors. These receptors then regulate the activation and differentiation of many innate and adaptive immune cells including mucocutaneous cell barriers, macrophages, neutrophils, dendritic cells, natural killer cells, innate-like lymphoid cells, and T and B lymphocytes. Mycobiome disruptions have been correlated with various diseases affecting mostly the brain, lungs, liver and pancreas. This work reviews our current knowledge on the mycobiome, focusing on its composition, research challenges, conditioning factors, interactions with the bacteriome and the immune system, and the known mycobiome alterations associated with disease.

17 September 2025 in Molecular Therapy
Verified
Journal Article
Open access
MAMaría Velasco-de Andrés
María Velasco-de Andrés
CCCristina Català
Cristina Català
LCLaura Carrillo-Serradell
Laura Carrillo-Serradell
VPVioleta Planells-Romeo
Violeta Planells-Romeo
LALucía Aragón-Serrano
Lucía Aragón-Serrano
LFLozano Francisco
Lozano Francisco
The treatment of invasive fungal infections (IFI) poses a major health challenge due to their severity, the scarcity and toxicity of current antifungal drugs, and the emergence of drug-resistant strains, thus forcing the search for novel strategies. Approaches involving adoptive transfer of immune cells harboring chimeric antigen receptors (CARs) are gaining momentum in several clinical settings. Based on the fungal β-glucan-binding properties of the lymphocyte scavenger receptor CD5, we assayed NK and T cells engineered with a CD5-based second generation CAR (SRCD5CAR) for the treatment of IFI. In vitro results revealed that SRCD5CAR expression specifically potentiates NK cell activation (i.e., CD69 expression and cytokine/chemokine production) and killing (i.e., CD107a expression and perforin/granzyme production) against different pathogenic fungal species (i.e., Candida albicans, Cryptococcus neoformans, Aspergillus fumigatus and Fusarium solani). Further in vivo infusion of SRCD5CAR-NK cells into fungal-infected NSG mice increased survival rates and decreased fungal burden in target organs. Similar in vitro and in vivo anti-fungal observations were also obtained for SRCD5CAR-T cells. Overall, the superior and specific performance exhibited by SRCD5CAR-transduced NK cells open new avenues for the development of novel off-the-shelf adoptive transfer of allogeneic cells against IFI, be those alone or adjunctive to antifungal drugs.

6 February 2023 in European Journal of Immunology
Verified
Journal Article
Open access
MAMaría Velasco-de Andrés
María Velasco-de Andrés
GMGuillermo muñoz
Guillermo muñoz
LCLaura Carrillo‐Serradell
Laura Carrillo‐Serradell
MGMaría del Mar Gutiérrez‐Hernández
María del Mar Gutiérrez‐Hernández
CCCristina Català
Cristina Català
LFLozano Francisco
Lozano Francisco
Adoptive cell transfer (ACT) therapies have gained renewed interest in the field of immunotherapy following the advent of chimeric antigen receptor (CAR) technology. This immunological breakthrough requires immune cell engineering with an artificial surface protein receptor for antigen‐specific recognition coupled to an intracellular protein domain for cell activating functions. CAR‐based ACT has successfully solved some hematological malignancies, and it is expected that other tumors may soon benefit from this approach. However, the potential of CAR technology is such that other immune‐mediated disorders are beginning to profit from it. This review will focus on CAR‐based ACT therapeutic areas other than oncology such as infection, allergy, autoimmunity, transplantation, and fibrotic repair. Herein, we discuss the results and limitations of preclinical and clinical studies in that regard.

6 October 2025 in Hepatology
Verified
Journal Article
Open access
AAAina Anton
Aina Anton
SSSarah Shalaby
Sarah Shalaby
MBMaría Luisa Botero
María Luisa Botero
ABAnnabel Blasi
Annabel Blasi
YFYiliam Fundora-Suárez
Yiliam Fundora-Suárez
VHVirginia Hernández-Gea
Virginia Hernández-Gea
Background and Aims: Portal vein thrombosis (PVT) is a frequent complication of cirrhosis, yet its pathophysiology remains elusive. Unlike thrombosis in other vascular beds, anticoagulation often fails to completely recanalize PVT, highlighting the need for greater mechanistic insight and alternative therapeutic approaches. Our study aimed to characterize the structural and cellular changes in the portal venous vascular bed to identify novel physiologically driven therapeutic targets. Approach and Results: Portal vein tissue specimens from explanted livers of patients with cirrhosis with and without PVT and from liver donors were histologically analyzed. PVT is associated with a remarkable eccentric thickening of the tunica intima due to accumulation of extracellular material and tunica intima increased cellularity. Transcriptomic analysis of human portal vein endothelial cells (PVEC) from patients with PVT identified the endothelial-to-mesenchymal transition (EndMT) pathway upregulated in PVECs from patients with PVT. In silico drug repurposing analysis identified statins as potential agents targeting these alterations. In vitro treatment with statins attenuated hallmarks of EndMT in primary human PVECs. Conclusions: In cirrhosis, the portal vein endothelium undergoes maladaptive remodeling marked by eccentric intimal hyperplasia, driven by ECM accumulation and infiltration of inflammatory and myofibroblast-like cells. This process narrows the lumen and may promote PVT. EndMT plays a key role in this transformation and emerges as a novel and promising therapeutic target. Notably, statins can attenuate EndMT, highlighting its potential in PVT treatment.

24 September 2024 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
GMGustavo Mourglia-Ettlin
Gustavo Mourglia-Ettlin
MGMaría Clara González-Porcile
María Clara González-Porcile
VRVioleta Planells Romeo
Violeta Planells Romeo
AAAntonella Long Albín
Antonella Long Albín
LCLaura Carrillo-Serradell
Laura Carrillo-Serradell
MAMaría Velasco-de Andrés
María Velasco-de Andrés
Cryptococcus neoformans is included in the World Health Organization fungal priority pathogen list, complied to expedite improved research and public-health interventions. The limited number of available antifungal drugs, their associated toxicity, and the emergence of drug-resistant strains make the development of new therapeutic strategies mandatory. Pattern-recognition receptors (PRRs) from the host’s innate immune system constitute a potential source of new antimicrobial agents. CD5 and CD6 are lymphoid members of the ancient scavenger receptor cysteine-rich superfamily (SRCR-SF) which bind pathogen-associated molecular patterns (PAMPs) of fungal and bacterial origin. Evidence supports the concept that such binding maps to 11-mer sequences present in each of their three SRCR extracellular domains. Herein, we have designed synthetic peptides containing tandems of such 11-mer sequences (namely CD5-T and CD6-T) and analyzed their C. neoformans-binding properties in vitro. Our results show both inhibitory effects on fungal growth and an ability to impact capsule formation and titanization, two critical virulence factors of C. neoformans involved in immune evasion. These effects hold promise for CD5-T and CD6-T peptides as single or adjuvant therapeutic agents against cryptococcosis.